RxDoctor Payments Data

Michelle Rhymestine, PA

Medical · Utica, NYNPI 1659311157

Payments from drug & device makers

$9,035in general payments, 2019–2025

Across 426 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$659
  • Gilead$625
  • Regeneron Healthcare Solutions, Inc.$497
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$482
  • plus $4K from 24 others

What the payments were for

  • Food & beverage$8,83198%
  • Education$2042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,035 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$1,912
Medicare patients
29
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin23$62,838
CreonLipase/Protease/Amylase11$37,967
LinzessLinaclotide31$32,054
Sucralfate50$6,776
SutabSod Sulf/Pot Chloride/Mag Sulf40$6,187
Omeprazole198$3,920
Esomeprazole Magnesium50$2,978
Famotidine95$2,189
Pantoprazole Sodium126$2,042
Dicyclomine Hcl50$1,948
CholestyramineCholestyramine (With Sugar)14$1,897
Budesonide DrBudesonide13$1,523
Lansoprazole17$810
Procto-Med HcHydrocortisone11$289
Ondansetron OdtOndansetron14$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,091$70,02142 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$482$62,83823 claims
Braintree Laboratories, Inc.Sutab$83$6,18740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.

Other medical in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →